Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction

Periodontitis, Chronic Clinical Trial

Official title:

Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction Immobilised on a Biodegradable Carrier

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04446897
• Other study ID #: IBCE_MSC(periodontitis)
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: August 3, 2020
• Est. completion date: December 31, 2020

Study information

• Verified date: February 2021
• Source: Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment of chronic medium-severe periodontitis with mesenchymal stem cells and mesenchymal stem cells predifferentiated in osteogenic direction

Description:

The bone defect will be filled with a porous membrane based on bone collagen measuring 5x5 mm or more with mesenchymal stem cells and mesenchymal stem cells predifferentiated in osteogenic direction

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years to 70 Years

Eligibility

Inclusion Criteria:

• chronic medium-severe periodontitis

Exclusion Criteria:

• pregnancy
• breast-feeding
• acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis
• mental disorders

Related Conditions & MeSH terms

• Chronic Periodontitis
• Periodontitis
• Periodontitis, Chronic

Intervention

Biological:
• mesenchymal stem cells
autologous mesenchymal stem cells

Other:
• standard treatment
standard treatment according to clinical protocols

Locations

Country	Name	City	State
Belarus	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	Minsk

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	Belarusian Medical Academy of Post-Graduate Education

Country where clinical trial is conducted

Belarus, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients cured	number of patients cured	1 month